eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | leukemia, acute myeloid |
| Comorbidity | C0026986|myelodysplastic syndromes |
| Sentences | 4 |
| PubMedID- 20178141 | Dna methyltransferase inhibitors are well tolerated in outpatient settings, with azacitidine prolonging survival and decreasing time to acute myeloid leukemia progression in patients with high-risk myelodysplastic syndromes. |
| PubMedID- 23137720 | Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories. |
| PubMedID- 23362656 | Azacitidine (5-azacytidine, vidaza) is a disease-modifying agent that improves survival, reduces transfusion dependence, and reduces progression to acute myeloid leukemia in patients with higher risk myelodysplastic syndromes. |
| PubMedID- 23494725 | The above scale is poorly correlated with overall survival or transformability into acute myeloid leukemia in patients with secondary myelodysplastic syndromes who constitute a large percentage of patients [44]. |
Page: 1